Related Experiment Videos
Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific
D J Nelson1, S Mukherjee, C Bundell
1Department of Medicine, University of Western Australia, Nedlands, Queen Elizabeth II Medical Center, Perth, Western Australia, Australia. delian@cyllene.uwa.edu.au
Abstract:
To determine whether APC function or "arming" of CTL for lytic function are the points at which Ags from a nonimmunogenic tumor fail to induce an effective immune response, we established a murine tumor model that expressed intracellular OVA and selected a clone (cOVA-9) that remained susceptible to lysis by specific CD8(+) T cells throughout tumor growth. Viable cOVA-9 tumor cells grew in normal mice at a rate similar to the parental tumor, and vaccination with irradiated cOVA-9 cells did not induce protection against itself or the parental line, confirming its nonimmunogenic status. In vivo evaluation during tumor growth demonstrated persisting tumor Ag cross-presentation accompanied by the generation of potent, specific CTL which were detectable when tumors were barely palpable. Despite the presence of highly active CTL in the tumor-draining lymph nodes, there was no apparent lysis of tumor-associated APC. These data show that tumor-draining APC are not dysfunctional with regard to two crucial processes, in vivo tumor Ag cross-presentation and specific CTL arming, and that failure to prevent tumor growth is not in the induction phase, but in the effector phase and occurs within the tumor itself before the tumor matrix is established.
Insights
Tumor cells evade immune attack not due to antigen presentation or T-cell activation, but because the tumor microenvironment prevents cytotoxic T-lymphocyte (CTL) from killing cancer cells. This immune evasion occurs early in tumor development.
Area of Science:
- Immunology
- Cancer Biology
- Tumor Microenvironment
Background:
- Nonimmunogenic tumors often evade immune surveillance.
- Understanding immune evasion mechanisms is crucial for developing effective cancer immunotherapies.
Purpose of the Study:
- To investigate whether antigen presentation or cytotoxic T-lymphocyte (CTL) "arming" is impaired in nonimmunogenic tumors.
- To identify the specific phase of the immune response where tumor growth fails to be inhibited.
Main Methods:
- Established a murine tumor model expressing intracellular ovalbumin (OVA).
- Selected a clone (cOVA-9) susceptible to CTL lysis throughout tumor growth.
- Evaluated in vivo antigen cross-presentation and CTL activity in tumor-draining lymph nodes.
Main Results:
- Nonimmunogenic tumors grew similarly to parental lines, even after vaccination.
- Potent, specific CTLs were generated, and antigen cross-presentation persisted.
- Despite active CTLs, tumor-associated antigen-presenting cells (APCs) were not lysed.
Conclusions:
- Tumor-draining APCs are functional in antigen cross-presentation and CTL arming.
- Immune evasion occurs in the effector phase within the tumor itself, not during induction.
- Failure to prevent tumor growth is linked to the tumor microenvironment's impact on CTL function before tumor matrix establishment.